Compact Pharmaceutical Manufacture Drug for Efferent Therapy - Enterosorbent ATC07

1. Central Research Laboratory BASOC Development, Implementation and Production Drugs for Efferent Therapy Compact Pharmaceutical Manufacture Drug for Efferent Therapy Enterosorbent ATC07 BASOC laboratory Kyiv City, Ukraine basoclab@gmail.com

2. A serious problem is the human intoxication following exogenous and endogenous poisoning Human intoxication occurs with diseases, poisoning, digestive disorders and many pathological processes Intoxication determines the severity of the general human condition and makes ones feel ill Recovery and maintenance of health requires elimination of toxins, pathogens and ballast substances from the body

3. Mission – to provide affordable and effective drugs for the treatment of intoxication Key measures to treat intoxication is enterosorption Enterosorption - means binding and excretion of endogenous and exogenous substances, supramolecular structures and cells from the gastrointestinal tract Enterosorbents - drugs for excretion pathogens from the gastrointestinal tract for the treatment and prevention of diseases

4. Broad-spectrum enterosorbent АТС07 is based on finely divided silica 1 gram forms 300 sq.m. of strongly absorbing surface high selective sorption of protein toxins remove the metabolic products and pathogens binds atherogenic cholesterol allows to halving the duration of treatment does not injure the mucous membrane of the gastrointestinal tract (GIT) allowed for all age categories no side effects

5. Prevention and treatment intestinal infections, dysentery detoxification DETOX atherosclerosis prevention food poisoning allergies diarrhea alcohol intoxication

6. Smecta АТС07 Active-carbon allergies alcohol intoxication food poisoning diarrhea dysbacteriosis intestinal infections liver cirrhosis peptic ulcer after radiation therapy renal failure chronic hepatitis

7. Price Analogs Sales and Profitability 25 g. $ 4–8 Smecta 150 000 2 M = = $ 450 000 $ 3 2 days 1 year Heilerde, Myrrhinil, Lefax € 10-15 smecta act. carbon 50% 300% Enterosgel, Polisorbum, Active-carbon $ 2–6 АТС07 АТС07

8. Description enterosorbent АТС07 Description light powder, white, tasteless, odorless Composition finely divided silica Substance the powder is intended for preparing an oral suspension Pharmachologic effect enterosorption and detoxification Pharmacodynamics absorbs protein toxins and pathogens in the lumen of the GIT Pharmacokinetics it is not absorbed in the GIT and excreted in the feces unchanged

9. Competitive advantages of production of the sorbent ATC07 Production АТС07 and raw materials low cost 3-5 pers. simple production Gegmany cycle possibility of production and delivery small batches minimum delivery time to 150 000 3 м3 consumers minimum storage costs of drugs minimum shipping 380V/50Gz 700 kw costs 200 м2

10. Technology and documentation of the sorbent АТС07 production Technical specifications 1 Production regulations 2 description of production Р1 hardware scheme of production and equipment specification Р2 technology settings Р3 general scheme of a quality control system Р4 industrial safety and environmental protection Р5 manuals Р6 scheme of production space Р7 norms of the raw materials, semi-finished products and energy Р8 characteristics of raw materials, semi-finished products Р9 Quality Control Techniques 3 Policy brief on enterosorbents use 4

11. Sorbents consumption in monetary terms Sorbents сonsumption in physical terms silica-sorbent 60% $ 125 M 87 million pack 80% active-carbon